Evidence map›Paper›PMID 34813858›Full record

ArticleMicrovascular research2022

Viable human brain microvessels for the study of aging and neurodegenerative diseases.

Mamatha Damodarasamy, Zin Z Khaing, Jeffrey Hyde, C Dirk Keene, Itay Bentov, William A Banks, May J Reed

Open access · greenAbstract read
In one paragraph

Article in Microvascular research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mamatha DamodarasamyDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA; VA Puget Sound Health Care System, Geriatric Research Education and Clinical Center, Seattle, WA, USA.
Zin Z KhaingDepartment of Neurosurgery, University of Washington, Seattle, WA, USA.
Jeffrey HydeDepartment of Neurosurgery, University of Washington, Seattle, WA, USA.
C Dirk KeeneDepartment of Laboratory Medicine and Pathology, Division of Neuropathology, University of Washington, Seattle, WA, USA.
Itay BentovDepartment of Pain and Anesthesia, University of Washington, Seattle, WA, USA.
William A BanksDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA; VA Puget Sound Health Care System, Geriatric Research Education and Clinical Center, Seattle, WA, USA.
May J ReedDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA; VA Puget Sound Health Care System, Geriatric Research Education and Clinical Center, Seattle, WA, USA. Electronic address: mjr@uw.edu.
University of Washington · USGeriatric Research Education and Clinical Center · US

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Furthering scientific understanding of mechanisms underlying resilience to the effects of AD pathology by incorporating state of the art quantification of gliosis, inflammation, & synaptic toxicityU01AG006781 · NIA · UNIVERSITY OF WASHINGTON · PI CRANE, PAUL K, LARSON, ERIC B · 1986 to 2020
$39.3M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Thomas J. Grabowski · 2020 to 2026
$29.0M
Intranasal Insulin in a Mouse Model of Alzheimer's DiseaseR01AG046619 · NIA · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI BANKS, WILLIAM A · 2014 to 2018
$2.4M
Viable Microvessels for the Study of the Microvasculature in Alzheimer's DiseaseR21AG073676 · NIA · UNIVERSITY OF WASHINGTON · PI REED, MAY J · 2021 to 2022
$428k
Hyaluronan and the microvascular and neuropathology of Alzheimer’s DiseaseR21AG056883 · NIA · UNIVERSITY OF WASHINGTON · PI REED, MAY J · 2017 to 2018
$427k
Defining microvascular structure and function in the aged cervical spinal cordR03AG073929 · NIA · UNIVERSITY OF WASHINGTON · PI KHAING, ZIN Z · 2022 to 2023
$156k
The Microvasculature in Alzheimer’s Disease: Viable Microvessels for Studies of Brain Endothelial and Glycocalyx HealthR03AG075397 · NIA · UNIVERSITY OF WASHINGTON · PI REED, MAY J · 2022 to 2022
$156k
The Brain Microvasculature, Hyaluronan, and AgingR03AG051071 · NIA · UNIVERSITY OF WASHINGTON · PI REED, MAY J · 2015 to 2016
$155k
NCATS NIH HHS UL1 TR002319NIA NIH HHS P30 AG066509NIA NIH HHS R01 AG046619NIA NIH HHS R03 AG051071NIA NIH HHS R03 AG073929NIA NIH HHS R03 AG075397NIA NIH HHS R21 AG056883NIA NIH HHS R21 AG073676NIA NIH HHS U01 AG006781
6 · The paper itself

Abstract

The brain microvasculature is altered in normal aging and in the presence of disease processes, such as neurodegeneration or ischemia, but there are few methods for studying living tissues. We now report that viable microvessels (MV) are readily isolated from brain tissue of subjects enrolled in studies of neurodegenerative diseases who undergo rapid autopsy (performed with <12 h postmortem interval - PMI). We find that these MV retain their morphology and cellular components and are fairly uniform in size. Sufficient MV (~3-5000) are obtained from 3 to 4 g of tissue to allow for studies of cellular composition as well as extracellular matrix (ECM). Using live/dead assays, these MV are viable for up to 5 days in tissue culture media (2D) designed to support endothelial cells and up to 11 days post-isolation in a 3-dimensional (3D) matrix (Low Growth Factor Matrigel™). Assays that measure the reducing potential of live cells \demonstrated that the majority of the MV maintain high levels of metabolic activity for a similar number of days as the live/dead assays. Functional cellular components (such as tight junctions and transporter proteins) and ECM of MV in tissue culture media, and to a lesser extent in 3D matrices, were readily visualized using immunofluorescence techniques. MV in tissue culture media are lysed and protein content analyzed, but MV in 3D matrix first require removal of the supporting matrix, which can confound the analysis of MV ECM. Finally, MV can be preserved in cryoprotective media, whereby over 50% retain their baseline viability upon thawing. In summary, we find that MV isolated from human brains undergoing rapid autopsy are viable in standard tissue culture for up to 5 days and the timeframe for experiments can be extended up to 11 days by use of a supportive 3D matrix. Viable human MV allow for temporal and spatial analysis of relevant cellular and ECM components that have implications for microvascular function in neurodegenerative diseases, vascular brain injury, and neurotrauma.

Indexed as

Age FactorsAgingAutopsyCell Culture Techniques, Three DimensionalCerebral CortexCryopreservationCulture MediaExtracellular MatrixHumansMicrovesselsNeurodegenerative DiseasesTime FactorsTissue Culture TechniquesTissue SurvivalCulture Media3D cultureBrainCryostorageIn vitroMicrovasculatureMicrovesselsViability

Identifiers

PMID34813858
PMCPMC8846932
OpenAlexW3214984145

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.